The effect of hysterectomy or levonorgestrel-releasing intrauterine system on cardiovascular disease risk factors in menorrhagia patients: A 10-year follow-up of a randomised trial

Maturitas

Volumn 69, Issue 4, 2011, Pages 354-358

  Heliovaara Peippo S ^a   Oksjoki, R ^b   Halmesmaki K ^a   Kaaja, R ^a   Teperi, J ^c   Grenman, S ^d   Kivela A ^e   Surcel, H M ^f   Tomas, E ^g   Tuppurainen, M ^h   Hurskainen, R ^a,i   Paavonen, J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Sosiaali ja terveysministerio   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g TAMPERE UNIVERSITY HOSPITAL   (Finland)

^h KUOPIO UNIVERSITY HOSPITAL   (Finland)

ⁱ HYVINKÄÄ HOSPITAL   (Finland)

Author keywords

Cardiovascular disease; Hysterectomy; Inflammation; LNG IUS; Menorrhagia

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; LEVONORGESTREL; LIPID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MENORRHAGIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; WAIST CIRCUMFERENCE;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; HYSTERECTOMY; INFLAMMATION; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA; MIDDLE AGED; PROGESTINS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959930088     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.05.004     Document Type: Article

References (30)

1. M. Shapley, K. Jordan, and P.R. Croft An epidemiological survey of symptoms of menstrual loss in the community Br J Gen Pract 54 2004 359 363 (Pubitemid 38584861)
2. R. Hurskainen, J. Teperi, and P. Rissanen Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial Lancet 357 2001 273 277 (Pubitemid 32120860)
3. R. Hurskainen, J. Teperi, and P. Rissanen Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up JAMA 291 2004 1456 1463 (Pubitemid 38543736)
4. C.M. Farquhar, L. Sadler, S.A. Harvey, and A.W. Stewart The association of hysterectomy and menopause: a prospective cohort study BJOG 112 2005 956 962 (Pubitemid 40896964)
5. K.H. Halmesmaki, R.A. Hurskainen, B. Cacciatore, A. Tiitinen, and J.A. Paavonen Effect of hysterectomy or LNG-IUS on serum inhibin B levels and ovarian blood flow Maturitas 57 2007 279 285 (Pubitemid 46900989)
6. K. Halmesmaki, R. Hurskainen, and A. Tiitinen A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms Hum Reprod 19 2004 378 382 (Pubitemid 38220011)
7. R. Punnonen, M. Ikalainen, and E. Seppala Premenopausal hysterectomy and risk of cardiovascular disease Lancet 1 1987 1139 (Pubitemid 17070137)
8. E. Kharazmi, M. Fallah, and R. Luoto Cardiovascular diseases attributable to hysterectomy: a population-based study Acta Obstet Gynecol Scand 86 2007 1476 1483 (Pubitemid 350135587)
9. A. Teichmann Pharmacology of estradiol valerate/dienogest Climacteric 6 Suppl. 2 2003 17 23
10. C. Westhoff Depot medroxyprogesterone acetate contraception, metabolic parameters and mood changes J Reprod Med 41 Suppl. 5 1996 401 406 (Pubitemid 26172581)
11. A. Biswas, O.A. Viegas, and A.C. Roy Effect of implanon and norplant subdermal contraceptive implants on serum lipids - a randomized comparative study Contraception 68 2003 189 193 (Pubitemid 38367487)
12. L. Morin-Papunen, H. Martikainen, and M.I. McCarthy Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population Am J Obstet Gynecol 199 2008 529.e1, e10
13. F Kayikcioglu, M. Gunes, O. Ozdegirmenci, and A. Haberal Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study Contraception 73 2006 528 531
14. Y. Zhang, E.T. Lee, L.D. Cowan, K.E. North, R.A. Wild, and B.V. Howard Hysterectomy prevalence and cardiovascular disease risk factors in American Indian women Maturitas 52 2005 328 336 (Pubitemid 41562205)
15. M. Stramba-Badiale, K.M. Fox, and S.G. Priori Cardiovascular diseases in women: a statement from the policy conference of the European society of cardiology Eur Heart J 27 2006 994 1005
16. P.M. Ridker, C.H. Hennekens, J.E. Buring, and N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843 (Pubitemid 30165206)
17. R. Hurskainen, J. Teperi, and U. Turpeinen Combined laboratory and diary method for objective assessment of menstrual blood loss Acta Obstet Gynecol Scand 77 1998 201 204 (Pubitemid 28075391)
18. B.V. Howard, L. Kuller, and R. Langer Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the women's health initiative observational study Circulation 111 2005 1462 1470 (Pubitemid 40470639)
19. M. Abu-Taha, C. Rius, and C. Hermenegildo Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan J Immunol 183 2009 1393 1402
20. J.E. Manson, M.A. Allison, and J.E. Rossouw Estrogen therapy and coronary-artery calcification N Engl J Med 356 2007 2591 2602 (Pubitemid 46961004)
21. J.E. Rossouw, R.L. Prentice, and J.E. Manson Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause JAMA 297 2007 1465 1477 (Pubitemid 46556472)
22. S. Kwok, D. Canoy, and W.D. Ashton Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom women's heart study (UKWHS) Clin Endocrinol (Oxf) 71 2009 727 732
23. A.L. Eilertsen, L. Sandvik, B. Steinsvik, and P.M. Sandset Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers J Thromb Haemost 6 2008 928 934 (Pubitemid 351689913)
24. M. Bochud, F. Marquant, and P.M. Marques-Vidal Association between C-reactive protein and adiposity in women J Clin Endocrinol Metab 94 2009 3969 3977
25. M.H. Wener, P.R. Daum, and G.M. McQuillan The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration J Rheumatol 27 2000 2351 2359
26. S. Woloshin, and L.M. Schwartz Distribution of C-reactive protein values in the United States N Engl J Med 352 2005 1611 1613 (Pubitemid 40517111)
27. A.D. Pradhan, J.E. Manson, and J.E. Rossouw Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the women's health initiative observational study JAMA 288 2002 980 987 (Pubitemid 34920463)
28. G.S. Hotamisligil The role of TNFalpha and TNF receptors in obesity and insulin resistance J Intern Med 245 1999 621 625 (Pubitemid 29278870)
29. I. Nieto-Vazquez, S. Fernandez-Veledo, D.K. Kramer, R. Vila-Bedmar, L. Garcia-Guerra, and M. Lorenzo Insulin resistance associated to obesity: the link TNF-alpha Arch Physiol Biochem 114 2008 183 194 (Pubitemid 352009305)
30. A. Amery, H. Wasir, and C. Bulpitt Aging and the cardiovascular system Acta Cardiol 33 1978 443 467 (Pubitemid 9104095)